




RealRate

PHARMACEUTICAL 2017

Vanda Pharmaceuticals Inc. Rank 106 of 292





RealRate

PHARMACEUTICAL 2017

Vanda Pharmaceuticals Inc. Rank 106 of 292



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 88% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 144%, being 141% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	174,175
Cost of Goods Sold	0
Intangible Assets	27,819
Liabilities, Current	50,320
Liabilities, Non-Current	3,724
Other Assets	3,365
Other Compr. Net Income	19
Other Expenses	35,749
Other Liabilities	25,000
Other Net Income	0
Other Revenues	146,682
Property and Equipment	5,015
Research and Development	29,156
Selling, General and Administrative Expense	99,787

Output Variable	Value in 1000 USD
Assets	210,374
Liabilities	79,044
Expenses	164,692
Revenues	146,682
Stockholders Equity	131,330
Net Income	-18,010
Comprehensive Net Income	-18,000
Economic Capital Ratio	144%